Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study
Considering the high price of the GLE/PIB compared with the available options in Iran, with the introduction of GLE/PIB into Iran's drug list, insurance coverage and appropriate allocation of necessary resources, a reduction in the cost burden because of hepatitis C treatment is expected for individuals and households. Additionally, with a well-regulated market share of existing medications, the optimal treatment choice for patients will be feasible.
Authors
- Mojtaba Jafari (ORCID: https://orcid.org/0000-0001-9456-471X)
- Ehsan Teymourzadeh (ORCID: https://orcid.org/0000-0002-3238-9853)
- Parisa Mehdizadeh (ORCID: https://orcid.org/0000-0002-2483-4646)
- Khosro Keshavarz (ORCID: https://orcid.org/0000-0002-5778-5502)
- Mohammad Ali Abyazi (ORCID: https://orcid.org/0000-0003-4123-3268)
- Parvez Shirazi
Institutions
- Zanjan University of Medical Sciences (IR)
- Baqiyatallah University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-092359
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00